Skip to content

Trial · Interventional

Status unknownNot applicableRegistry data

The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons

NCTNCT00969644 (opens ClinicalTrials.gov in a new tab)Other idHC-2009-049
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Status unknown
Phase
Not applicable
Enrollment
12 participants (estimated)
Sponsor
Herlev Hospital · Other
Design
Randomized · Open label (no masking)
Countries
1 country

Denmark

Start
Sept 2009
Primary completion
Mar 2010 (estimated)
Completion
Mar 2010 (estimated)
First posted
1 Sept 2009 (estimated)
Last update posted
1 Sept 2009 (estimated)
Conditions
Interaction Between the GH/IGF-I System and the Immune-system

Timeline

1 trial

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
200920102011
  1. N/A

    The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons

    NCT00969644

    Sept 2009 to est. Mar 2010

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Observations in patients with growth hormone (GH)-disturbances have suggested that GH/IGF-I might have anti-inflammatory effects. To elucidate this hypothesis the investigators have planned a study to investigate if 3 weeks administration of GH and subsequently the GH antagonist Pegvisomant (or vice versa) influence serum levels of different inflammatory markers in healthy volunteers.

Interventions

  • SomatropinDrug
  • PegvisomantDrug

Arms2

  • Active comparator

    GH

  • Active comparator

    Pegvisomant

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. The relationship between changes in serum levels of Tumor Necrosis Factor α (TNF-α), Interleukin-6 (IL-6), high sensitive CRP (hsCRP) and YKL-40 vs. changes in serum levels og IGF-I

    Time frame · 1/9 2009 - 1/3 2010

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2013

3 results

Growth hormone (GH) activity is associated with increased serum oestradiol and reduced anti-Müllerian hormone in healthy male volunteers treated with GH and a GH antagonist.

Andreassen et al. 2013Andrologycited by 16

PMID 23785020DOI 10.1111/j.2047-2927.2013.00096.xPUB-23785020

Rights unknown3 results
Source linkSee results (3)

Eligibility

Who could join, as posted.

Sex
All
Age
from 22 Years up to 65 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Healthy, normal blood tests Exclusion Criteria: * Previous cancer

PepBank is a research reference. Talk to a doctor before you use any peptide.